How does the dosage for semaglutide injections actually work?

Why does the dose start so low before reaching 2.4 mg?

A lot of people assume the first pen is doing very little. That's a reasonable thought, 0.25 mg is a small number. But the opening dose exists to let your digestive system adjust to the way semaglutide slows gastric emptying, rather than to produce significant weight loss straight away. Jumping to a higher dose from week one would make side effects far harder to manage for most people.

The four-step climb (0.25 mg, then 0.5 mg, then 1.0 mg, then 1.7 mg, before reaching the 2.4 mg maintenance level) typically unfolds over roughly sixteen weeks. Each stage lasts around four weeks. Some people move through it smoothly; others need longer at a particular step because nausea or other gastrointestinal effects haven't settled. Both are normal. The full semaglutide dose schedule is worth understanding before you start, so the early weeks don't feel like stalling.

The NHS medicines page for semaglutide covers the general escalation pattern alongside information on common side effects, and it's a good first read alongside whatever your prescriber has outlined for you specifically.

What happens once someone reaches 2.4 mg, is that always the final dose?

For most people prescribed Wegovy, 2.4 mg weekly has been the standard maintenance level. Clinical trials at this dose produced around 15% average body-weight reduction over 68 weeks, as reported in the STEP 1 trial published in the New England Journal of Medicine.

In January 2026, however, the MHRA approved a 7.2 mg dose (initially delivered as three 2.4 mg pens administered weekly) and in April 2026 a dedicated single-dose 7.2 mg pen was approved for adults with a BMI of 30 or above. Trials reported around 20.7% average weight loss over 72 weeks at this higher level, which narrows the gap with tirzepatide results. The starting dose remains 0.25 mg even for patients who will eventually reach 7.2 mg, with escalation steps set by the prescriber in the same four-weekly pattern.

Whether 7.2 mg is appropriate for a given individual is not something the dose schedule decides on its own. A prescriber considers tolerability history, current weight, and clinical goals. If you want to understand how Wegovy's different dose strengths compare in practical terms, that page covers what each level looks like and who it tends to suit.

Can the dose be reduced or paused, and what prompts that?

Yes, and this is more common than many people expect. If side effects become disruptive at a given step, the prescriber may recommend holding at the current dose for an extra four weeks rather than increasing, or stepping down temporarily. The goal is to find the highest dose that's both effective and tolerable for that person, not to race to the maximum.

A pause in dose increases isn't a setback; it's the schedule being used as it was intended. What's not appropriate is adjusting doses independently based on how you feel, the timing and direction of any change should always go through the prescriber or the clinical team supporting your treatment.

For context on how semaglutide sits within the range of licensed weight-loss options, the weight-loss treatment overview sets out what's available and how the different medicines compare at a broad level. And if you're curious how the dose-for-weight-loss angle specifically is addressed in the evidence, the dosage guidance for weight loss page goes into more clinical detail.

Does everyone follow the same schedule, or does it vary by person?

The licensed titration schedule is the same starting framework for everyone, same steps, same nominal timing. What varies is how each individual moves through it. If you're progressing well and want to understand what comes next, the semaglutide 5mg injection page explains what that mid-escalation stage involves and what to expect from it. For those approaching the upper end of the schedule, the semaglutide 10mg injection page covers the higher-dose step in detail, including how it fits into the overall titration pattern.

Clinical guidance from NICE, in its appraisal of semaglutide for weight management, notes that if less than 5% weight loss is achieved after six months on the maintenance dose, continuing treatment should be reviewed. That kind of checkpoint is built into good clinical oversight, it's one reason a one-off prescription without ongoing clinical review isn't really a complete service.

At nume, every repeat order goes through a fresh clinical review by a GPhC-registered prescriber before anything is dispensed. There's no auto-renewal. If you'd like to talk through where you are in the schedule, or whether semaglutide is the right fit to begin with, our clinical team is available seven days a week. A useful reference for the full picture of how dosage interacts with treatment outcomes is the Wegovy dosage chart, which lays out the steps in a clear visual format. For questions about cost alongside clinical oversight, the weight-loss treatments page is the right place to look at what's included. Check your eligibility there to get started.